| Generic Drug Name |
| Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free | Rotavirus Vaccine, Live, Oral Pentavalent | Pneumococcal 23 Vaccine Polyvalent | Hepatitis A Virus Vaccine, Preservative Free |
| Features and Benefits |
|
- GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
- Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein
- Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months
- Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58
|
- The vaccination series consists of three ready-to-use liquid doses of RotaTeq* administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4 to 10 week intervals
- 10 individually pouched single dose tubes
- Each dose is supplied in a container consisting of a squeezable plastic dosing tube with a twist-off cap, allowing for direct oral administration
|
- PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine
- PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged >2 years who are at increased risk for pneumococcal disease
- Box of 10 single-dose, pre-filled Luer-Lok™ syringes with tip caps, color coded with a violet plunger rod and purple stripe on the syringe labels and cartons
- Store unopened and opened vials at 2° - 8°C (36° - 46°F)
|
- VAQTA® [Hepatitis A Vaccine, Inactivated] is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older
- VAQTA is a sterile suspension for intramuscular injection
- One milliliter of the vaccine contains approximately 50U of hepatitis A virus antigen, which is purified and formulated without a preservative
- Each 0.5-mL pediatric dose contains 25U of hepatitis A virus antigen and adsorbed onto approximately 0.225 mg of aluminum provided as amorphous aluminum hydroxy phosphate sulfate, and 35 mcg of sodium borate as a pH stabilizer, in 0.9% sodium chloride
|
